Cite

HARVARD Citation

    Kim, J. et al. (2020). Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs. Oncologist. pp. 348-354. [Online]. 
  
Back to record